Study examines drug labeling and exposure in infants

Federal legislation encouraging the study of drugs in pediatric patients has resulted in very few labeling changes that include new infant information, according to a study by Matthew M. Laughon, M.D., M.P.H., of the University of North Carolina at Chapel Hill, and colleagues.

Neonates (infants up to 28 days of age) are at high risk of -related adverse events and their unique physiology makes it hard to extrapolate data on drugs from older patients. Drug labeling often has insufficient information on the safety, efficacy or dosing that is appropriate for children, in part because there are few drug trials in neonates, according to the study background.

Researchers reviewed drug studies that included neonates, as a result of legislation, and assessed the types of drug labeling changes, if any, that were made. They reviewed Food and Drug Administration (FDA) databases and identified 28 drugs studies in neonates and 24 related labeling changes.

Study findings indicate 11 (46 percent) of the 24 neonatal labeling changes made clear the drug was approved for use in neonates on the basis of safety and effectiveness. Researchers then found that most of the studied drugs were not used in units (NICUs), with 13 (46 percent) of the 28 drugs studied in neonates not used and 8 (29 percent) of the drugs used in fewer than 60 neonates.

"Because of these challenges of performing clinical trials in infants, few labeling changes have included infant-specific information. Novel trial designs need to be developed and appropriate study end points must be identified and validated," the study concludes. "Education of parents and caregivers regarding the need for studies of drugs being given to will also increase trial success. The scientific and clinical research community will need to work together with the FDA to conduct essential neonatal studies."

More information: JAMA Pediatr. Published online December 9, 2013. DOI: 10.1001/jamapediatrics.2013.4208

add to favorites email to friend print save as pdf

Related Stories

Most newly approved biologics studied in peds population

Jan 15, 2013

(HealthDay)—The majority of biologics approved since 1997 include pediatric information in their labeling and have been studied in pediatric trials, according to a review published online Jan. 14 in Pediatrics.

Federal laws have enhanced pediatric drug studies

Feb 29, 2012

Federal laws that motivate or require drug and biologic developers to conduct pediatric studies have yielded beneficial information to guide the use of medications in children, says a new report by the Institute of Medicine. ...

Recommended for you

Helping babies survive

12 hours ago

A healthy baby is born in the Haydom Lutheran Hospital in Tanzania. She is given the name Precious and her proud mother is ready to take her back to the village. Many children born in the same hospital, or ...

Unstable child care can affect children by age four

Nov 20, 2014

A new study from UNC's Frank Porter Graham Child Development Institute (FPG) reveals that disruptions in child care negatively affect children's social development as early as age 4. However, the study also ...

Parental involvement still essential in secondary school

Nov 20, 2014

Although students become more independent as they rise through grade levels and parent-teacher interactions typically lessen as students age, parental involvement in a child's education during the secondary ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.